Heidi Fritz1, Gillian Flower2, Laura Weeks2, Kieran Cooley3, Michael Callachan1, Jessie McGowan1, Becky Skidmore1, Leesa Kirchner4, Dugald Seely5. 1. Canadian College of Naturopathic Medicine, Toronto, Ontario, Canada. 2. Ottawa Integrative Cancer Centre, Ottawa, Ontario, Canada. 3. Canadian College of Naturopathic Medicine, Toronto, Ontario, Canada University of Toronto, Toronto, Ontario, Canada. 4. Carp Ridge Natural Health Clinic, Carp, Ontario, Canada. 5. Canadian College of Naturopathic Medicine, Toronto, Ontario, Canada Ottawa Integrative Cancer Centre, Ottawa, Ontario, Canada Ottawa Hospital Research Institute, Ottawa, Ontario, Canada dseely@oicc.ca.
Abstract
BACKGROUND: Intravenous vitamin C (IVC) is a contentious adjunctive cancer therapy, widely used in naturopathic and integrative oncology settings. We conducted a systematic review of human interventional and observational studies assessing IVC for use in cancer patients. METHODS: We searched MEDLINE, EMBASE, The Cochrane Library, CINAHL, and AMED from inception to April 2013 for human studies examining the safety, effectiveness, or pharmacokinetics of IVC use in cancer patients. RESULTS: Of 897 records, a total of 39 reports of 37 studies were included: 2 randomized controlled trials (RCTs), 15 uncontrolled trials, 6 observational studies, and 14 case reports. IVC dosing ranged from 1 g to more than 200 g ascorbic acid per infusion, typically administered 2 to 3 times weekly. IVC does not appear to increase toxicity or interfere with antitumor effects of gemcitabine/erlotinib therapy or paclitaxel and carboplatin. Based on 1 RCT and data from uncontrolled human trials, IVC may improve time to relapse and possibly enhance reductions in tumor mass and improve survival in combination with chemotherapy. IVC may improve quality of life, physical function, and toxicities associated with chemotherapy, including fatigue, nausea, insomnia, constipation, and depression. Case reports document several instances of tumor regression and long-term disease-free survival associated with use of IVC. CONCLUSION: There is limited high-quality clinical evidence on the safety and effectiveness of IVC. The existing evidence is preliminary and cannot be considered conclusive but is suggestive of a good safety profile and potentially important antitumor activity; however, more rigorous evidence is needed to conclusively demonstrate these effects. IVC may improve the quality of life and symptom severity of patients with cancer, and several cases of cancer remission have been reported. Well-designed, controlled studies of IVC therapy are needed.
BACKGROUND: Intravenous vitamin C (IVC) is a contentious adjunctive cancer therapy, widely used in naturopathic and integrative oncology settings. We conducted a systematic review of human interventional and observational studies assessing IVC for use in cancerpatients. METHODS: We searched MEDLINE, EMBASE, The Cochrane Library, CINAHL, and AMED from inception to April 2013 for human studies examining the safety, effectiveness, or pharmacokinetics of IVC use in cancerpatients. RESULTS: Of 897 records, a total of 39 reports of 37 studies were included: 2 randomized controlled trials (RCTs), 15 uncontrolled trials, 6 observational studies, and 14 case reports. IVC dosing ranged from 1 g to more than 200 g ascorbic acid per infusion, typically administered 2 to 3 times weekly. IVC does not appear to increase toxicity or interfere with antitumor effects of gemcitabine/erlotinib therapy or paclitaxel and carboplatin. Based on 1 RCT and data from uncontrolled human trials, IVC may improve time to relapse and possibly enhance reductions in tumor mass and improve survival in combination with chemotherapy. IVC may improve quality of life, physical function, and toxicities associated with chemotherapy, including fatigue, nausea, insomnia, constipation, and depression. Case reports document several instances of tumor regression and long-term disease-free survival associated with use of IVC. CONCLUSION: There is limited high-quality clinical evidence on the safety and effectiveness of IVC. The existing evidence is preliminary and cannot be considered conclusive but is suggestive of a good safety profile and potentially important antitumor activity; however, more rigorous evidence is needed to conclusively demonstrate these effects. IVC may improve the quality of life and symptom severity of patients with cancer, and several cases of cancer remission have been reported. Well-designed, controlled studies of IVC therapy are needed.
Authors: Luisa Cimmino; Igor Dolgalev; Yubao Wang; Akihide Yoshimi; Gaëlle H Martin; Jingjing Wang; Victor Ng; Bo Xia; Matthew T Witkowski; Marisa Mitchell-Flack; Isabella Grillo; Sofia Bakogianni; Delphine Ndiaye-Lobry; Miguel Torres Martín; Maria Guillamot; Robert S Banh; Mingjiang Xu; Maria E Figueroa; Ross A Dickins; Omar Abdel-Wahab; Christopher Y Park; Aristotelis Tsirigos; Benjamin G Neel; Iannis Aifantis Journal: Cell Date: 2017-08-17 Impact factor: 41.582
Authors: Junxiu Li; Chaorui Guo; Fan Feng; Ali Fan; Yu Dai; Ning Li; Di Zhao; Xijing Chen; Yang Lu Journal: Sci Rep Date: 2016-12-09 Impact factor: 4.379
Authors: Matthew R D'Costa; Nelson S Winkler; Dawn S Milliner; Suzanne M Norby; LaTonya J Hickson; John C Lieske Journal: Am J Kidney Dis Date: 2019-03-22 Impact factor: 8.860
Authors: Pavel Klener; Matthew Scott Alexander; Joseph John Cullen; Vera Stejskal; Jiri Sliva; Lucie Kotlarova; Pavel Kostiuk; Zdenek Prochazka; Marta Kucerova Journal: J Appl Biomed Date: 2020-02-19 Impact factor: 1.797